Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer

Peer Review reports

Original Submission
13 May 2013	Submitted	Original manuscript
Resubmission - Version 2
	Submitted	Manuscript version 2
25 May 2013	Author responded	Author comments - Gunnar Folprecht
Resubmission - Version 3
25 May 2013	Submitted	Manuscript version 3
26 Sep 2013	Reviewed	Reviewer Report - Hans-Joachim Schmoll
6 Apr 2014	Reviewed	Reviewer Report - Tae Won Kim
24 Jun 2014	Author responded	Author comments - Gunnar Folprecht
Resubmission - Version 4
24 Jun 2014	Submitted	Manuscript version 4
Publishing
16 Jul 2014	Editorially accepted
19 Jul 2014	Article published	10.1186/1471-2407-14-521

Back to article page